United States:
Dr. Ashish M. Kamat is an Endowed Professor of Urologic Oncology (Surgery) and Cancer Research, and the Director of the Bladder Cancer Support Program at University of Texas MD Anderson Cancer Center in Houston. He is the founding President of the International Bladder Cancer Group (IBCG) and serves as the Associate Cancer Center Director at the RFHNH Hospital in Mumbai. Dr. Kamat specializes in genitourinary cancers, with a particular focus on immunotherapy for urothelial cancers.
Denmark:
Prof Bente Thoft Jensen is a Clinical Nurse Specialist and Assistant Professor at the Department of Urology, Aarhus University Hospital, and the Department of Clinical Medicine, Aarhus University. She also serves as Section Leader in Prehabilitation at the National Centre of Research in Cancer Surgery (ACROBATIC) in Denmark.
She has been working in urology for over 30 years, in both Copenhagen and Aarhus. In 2015, she completed a postdoctoral fellowship at Memorial Sloan Kettering Cancer Center in New York,
France:
Dr Eva Maria Compérat is a renowned professor of Urologic Pathology at the Medical University of Vienna and the Head of the Department of Pathology at the Hôpital Tenon, Sorbonne University in Paris. She has made significant contributions to the field of Uropathology and has published several works in this area. Her research focuses on bladder cancer/urothelial carcinomas and the early events of bladder cancer development, upper urinary tract carcinomas, prostate cancer,
Brasil:
Dr Fernando Maluf, MD, PhD, is Director of Medical Oncology at Beneficência Portuguesa and a member of the steering committee of the Medical Oncology Centre at Albert Einstein Hospital in São Paulo, Brazil.
He is a member of the American Society of Clinical Oncology and a founding member of the Brazilian Group of Gynaecological Tumours (Grupo Brasileiro de Tumores Ginecológicos). Dr Maluf has authored numerous publications and currently serves as an editor for the Brazilian Oncology Manual.
Hong Kong:
Dr Jeremy Teoh is currently Associate Professor, and the Assistant Dean (External Affairs) of the Faculty of Medicine, The Chinese University of Hong Kong. In 2021, he was awarded the Ten Outstanding Young Persons Award (Hong Kong) and the SIU-Innovators Award. In 2023, he was appointed as an Adjunct Professor at the Medical University of Vienna. In 2024, he was awarded the World Chinese Urological Society Rising Star Award. Jeremy has an immense interest in bladder cancer research.
Morocco: Dr Oualla completed her medical training at University Sidi Mohamed Ben Abdellahprior to practicing as a Medical Oncologist at Hassan II University Hospital. She alsoearned a degree in epidemiology and clinical research from University Sidi MohamedBen AbdellahthenjoinedInstitut Jules Bordet in Brussels, Belgium, as an assistantdoctor (2012–2013).Dr Oualla holds a certificate of specialization in MedicalOncology from the Université Libre de Bruxelles, and completed a 3-yearpostgraduate course in Medical Oncology (European Organisation for Research andTreatment of Cancer [EORTC]-affiliated National Belgian Programme for Inter-University Faculty).
India: Dr Makarand Khochikar is a world renowned Urologic Oncologist with a vast experience of 30 years. He was trained in Mumbai and Nadiyad for Urology (1989-1992) and had further specialty training in London and Cambridge (1993-1998). He returned to India in 1998 and did pioneering work in establishing Urologic Oncology as a sub-specialty and has made his presence felt nationally and internationally through his exemplary work.
Dr Khochikar has an outstanding and glorious career.
Chile: Dr Mario I. Fernández, MD, is Associate Professor in the Department of Urology at the Faculty of Medicine, Clínica Alemana Universidad del Desarrollo in Santiago, Chile.
He serves on the Board of the Sociedad Chilena de Urología, is Editor-in-Chief of Revista Chilena de Urología, and leads the Bladder Cancer Working Group of the Latin American Urological Confederation (CAU). He is also a member of the IBCG Core Committee. Dr Fernández serves on the editorial boards of Bladder Cancer and Journal of Urology Open Plus,
France: Dr Molly Ingersoll received her PhD from NYU School of Medicine, where she studied host–pathogen interactions with Arturo Zychlinsky at both NYU and the Max Planck Institute for Infection Biology in Berlin, Germany. She completed a brief postdoctoral fellowship at Washington University School of Medicine in St Louis, Missouri, focusing on innate immunity to urinary tract infections with Scott Hultgren, followed by a postdoctoral appointment at Mount Sinai Medical Center in New York City,
United States: Dr Patrick Hensley is an Assistant Professor in the Departments of Urology and Pathology at the University of Kentucky College of Medicine in Lexington, Kentucky. He completed a Society of Urologic Oncology (SUO) fellowship in Urologic Oncology at the University of Texas MD Anderson Cancer Center. His clinical and academic focus is on urothelial carcinoma of the bladder and upper tract.
Dr Hensley’s research centres on predictive biomarkers in the muscle-invasive setting and approaches to bladder preservation.
